Technical Analysis for DRRX - DURECT Corporation

Grade Last Price % Change Price Change
grade B 1.75 2.94% 0.05
DRRX closed up 2.94 percent on Friday, September 13, 2019, on 44 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical DRRX trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 2.94%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.94%
Wide Bands Range Expansion 2.94%
Down 3 Days in a Row Weakness 2.94%
MACD Bearish Signal Line Cross Bearish 1.74%
Wide Bands Range Expansion 1.74%

Older signals for DRRX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
DURECT Corporation, a specialty pharmaceutical company, develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. It focuses on the development of products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, cardiovascular disease, and other chronic diseases. The company manufactures and sells ALZET osmotic pumps used in laboratory research; and a range of LACTEL standard and custom biodegradable polymers and excipients used as raw materials for the pharmaceutical and medical device clients. Its product pipeline includes REMOXY, an oral oxycodone gelatin capsule for chronic pain, which has received complete response letter from the U.S. Food and Drug Administration (FDA); POSIDUR, a Phase III clinical trial release formulation of bupivacaine for the treatment of post-surgical pain; ELADUR, a Phase II transdermal bupivacaine patch intended to provide delivery of bupivacaine; and TRANSDUR, a Phase II transdermal sufentanil patch intended to provide delivery of sufentanil. The company's products pipeline also comprises ORADUR-based opioids, including hydrocodone and hydromorphone for the treatment of pain, which are in Phase I clinical trial; oxymorphone, an ORADUR-based opioid for which IND has been accepted by the FDA; ORADUR-ADHD, a drug candidate in Phase I clinical trial for the treatment of attention deficit hyperactivity disorder; and Relday, an injectable risperidone product in Phase I clinical trial used to treat the symptoms of schizophrenia and bipolar I disorder. It is also involved in developing various biologics programs/research programs in other therapeutic categories. DURECT Corporation has strategic agreements with Hospira, Inc., Nycomed Danmark ApS; Pain Therapeutics, Inc.; Zogenix, Inc.; and Pfizer Inc. The company was founded in 1998 and is headquartered in Cupertino, California.
Pharmaceutical Pain Chemical Compounds Organic Compounds Schizophrenia Euphoriants Chronic Pain Cardiovascular Disease Central Nervous System Disorders Morphinans Attention Deficit Hyperactivity Disorder Ethers Opioids Phenols Chronic Diseases Fentanyl Drug Delivery Technology Treatment Of Attention Deficit Hyperactivity Disorder Hydromorphone Oxymorphone Sufentanil
Is DRRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 1.88
52 Week Low 0.46
Average Volume 1,089,820
200-Day Moving Average 0.8045
50-Day Moving Average 1.2484
20-Day Moving Average 1.617
10-Day Moving Average 1.733
Average True Range 0.1107
ADX 41.6
+DI 25.3245
-DI 17.7375
Chandelier Exit (Long, 3 ATRs ) 1.5479
Chandelier Exit (Short, 3 ATRs ) 1.5521
Upper Bollinger Band 1.9068
Lower Bollinger Band 1.3272
Percent B (%b) 0.73
BandWidth 35.844156
MACD Line 0.1437
MACD Signal Line 0.1575
MACD Histogram -0.0137
Fundamentals Value
Market Cap 257.24 Million
Num Shares 147 Million
EPS -0.26
Price-to-Earnings (P/E) Ratio -6.73
Price-to-Sales 7.10
Price-to-Book 0.00
PEG Ratio -0.16
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.89
Resistance 3 (R3) 1.87 1.82 1.86
Resistance 2 (R2) 1.82 1.78 1.82 1.85
Resistance 1 (R1) 1.78 1.76 1.80 1.80 1.85
Pivot Point 1.73 1.73 1.74 1.73 1.73
Support 1 (S1) 1.69 1.69 1.71 1.71 1.65
Support 2 (S2) 1.64 1.67 1.64 1.65
Support 3 (S3) 1.60 1.64 1.64
Support 4 (S4) 1.62